| Market Capitalization (Millions $) |
161 |
| Shares
Outstanding (Millions) |
87 |
| Employees |
20 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-26 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Cardiol Therapeutics Inc. is a Canadian biotechnology company that focuses on the research and development of cardiovascular therapies. The company is dedicated to developing innovative treatments for heart diseases, which are among the leading causes of death worldwide.
Cardiol Therapeutics utilizes a proprietary platform technology called CardiolRx to create pharmaceutical-grade cannabidiol (CBD) formulations. CBD is a non-psychoactive compound derived from the cannabis plant that has shown potential therapeutic benefits for various cardiovascular conditions, including heart failure and inflammation.
The company aims to leverage its expertise in CBD and cardiovascular medicine to enhance the effectiveness of existing therapies and develop novel treatments to address the unmet medical needs in the cardiovascular space. Cardiol Therapeutics is actively engaged in clinical trials and collaborations with leading research institutions and healthcare organizations to advance its product pipeline.
In addition to its pharmaceutical development efforts, Cardiol Therapeutics also operates a medical cannabis division called Cardiol Cannabis. This division focuses on the extraction, refinement, and commercialization of pharmaceutical-grade CBD products for the emerging medical cannabis market.
Overall, Cardiol Therapeutics Inc. is dedicated to improving the lives of patients with cardiovascular diseases through the development of innovative CBD-based therapies and medical cannabis products.
Company Address: 2265 Upper Middle Road East Oakville 0 ON
Company Phone Number: 910-0850 Stock Exchange / Ticker: NASDAQ CRDL
|
1.73%